北京若生智能科技有限公司
Drug Database
PG

PG-201 (Layla / PG201)

✓ Approved

PMG Pharm · 治疗药物

什么是 PG-201？

PG-201 是一种治疗药物，由PMG Pharm研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Layla, PG201
公司PMG Pharm
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, PMG Pharm

治疗适应症

PG-201 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersOsteoarthritis✓ Approved
Musculoskeletal and connective tissue disordersRheumatoid arthritisPhase III

相关研究文献

PubMedNature communications2026-10-26

ARHGEF2 isoform switching couples intestinal epithelial barrier function with autophagic host defense response to pathogens.

Chen Shuyuan S, Diwaker Alka A, Li Xi X, Salamah Abdulmajeed A et al.

Intestinal epithelial integrity is essential for host defense, yet how epithelial junctional scaffolds coordinate antimicrobial immunity remains unclear. We show that the long GEF-H1 isoforms (mouse Arhgef2-207; human ARHGEF2-219) localize to adherens junctions in polarized epithelial cells through interactions with actin and Nectin-3, whereas the shorter Arhgef2-201 isoform localizes to tight junctions. Conditional deletion of epithelial Arhgef2-207 induces Arhgef2-201 expression, disrupts barrier integrity, activates autophagy, and causes small-intestinal inflammation. In human intestinal organoids, Listeria monocytogenes selectively depletes junction-associated ARHGEF2-219, triggering a switch to ARHGEF2-201 and RhoA- and STING-mediated autophagic signaling. This transition coincides with loss of the Na⁺/K⁺-ATPase and epithelial polarity. Here we show that a pathogen-induced ARHGEF2 isoform switch links junctional perturbation to autophagic responses and immune activation, revealing a mechanism that couples barrier disruption to cell-intrinsic antimicrobial defense.

PMID 42928288
阅读全文 →
PubMedAnnals of clinical and translational neurology2026-10-26

Myostatin/Smad3 in Spinal Muscular Atrophy: Biomarkers of Disease Severity and Treatment Response.

Riolo Giorgia G, Dosi Claudia C, Parravicini Stefano S, Zanin Riccardo R et al.

Given the role of Myostatin (MSTN) in muscle homeostasis and its modulation by current spinal muscular atrophy (SMA) therapies, we investigated serum MSTN and, for the first time, its downstream effector Smad3 as candidate non-invasive biomarkers in SMA patients undergoing disease-modifying therapies (DMTs). The study included pediatric and adult SMA patients receiving DMTs (Nusinersen = 15; Risdiplam = 15), and participants in anti-MSTN clinical trials (n = 7), whose data were analyzed only at baseline. Serum MSTN and Smad3 levels were quantified by ELISA at baseline, 6 and 14 months post-treatment in pediatric and adult SMA patients, respectively, considering the slower DMTs effects in adulthood. Baseline MSTN levels were significantly (p-value < 0.05) higher in: males (915.0 ± 592.5 pg/mL) vs. females (593.4 ± 231.4 pg/mL); SMA III (952.2 ± 598.9 pg/mL) vs. II (541.1 ± 326.4 pg/mL), and walkers (1047.6 ± 548.9 pg/mL) vs. non-sitters (374.6 ± 188.5 pg/mL). Smad3 showed no correlation and remained stable during treatment. In adults MSTN levels positively correlated with Hammersmith Functional Motor Scale Expanded (HFMSE) at baseline (p = 0.01) and post-treatment (p = 0.003). Smad3 levels negatively correlated with baseline HFMSE (p = 0.03) and post-treatment Revised Upper Limb Module scores (p = 0.03). In pediatric patients, MSTN fold change (i.e., post-/pre-therapy ratio) at baseline negatively correlated with HFMSE changes (p = 0.008). MSTN levels were associated with clinical phenotype and motor function, supporting its role as a candidate biomarker of SMA severity in adult and pediatric patients. Our findings also suggest that MSTN may serve as a potential dynamic biomarker of disease progression in pediatric patients, regardless of treatment. Further validation in independent cohorts is warranted.

PMID 42929233
阅读全文 →
PubMedClinical oral implants research2026-10-26

One-Year Outcomes of Chairside Fully Guided Versus Conventional Partially Guided Implant Placement With Transcrestal Sinus Augmentation: A Randomized Controlled Trial.

Lee Jungwon J, Baek Yeon-Wha YW, Kim Jongseung J, Park Jin-Young JY et al.

This study represents the 1-year follow-up of a previously reported randomized controlled trial comparing chairside fully guided (FG) flapless implant placement with conventional partially guided (PG) open-flap implant placement. We evaluated marginal bone level (MBL) change, peri-implant clinical outcomes, and associations between placement accuracy and MBL change. This study was a 1-year follow-up analysis of a previously reported randomized controlled trial. Fifty-six patients were randomized into the FG (n = 28) and PG (n = 28) groups. Radiographic MBL changes and peri-implant clinical indices were evaluated at baseline and 1-year post-loading. Deviations between the virtually planned and placed implants were quantified in three dimensions. Stepwise multiple linear regression analyses were performed to identify accuracy parameters associated with MBL changes. Twenty-one FG and 22 PG patients completed follow-up. Peri-implant clinical parameters were comparable between groups. In unadjusted analyses, the FG group showed more positive mesial and mean ΔMBL values than the PG group. However, the treatment group was not significantly associated with mesial, distal, or mean ΔMBL in the adjusted models. Implant accuracy was higher in the FG group, with lower horizontal, three-dimensional, and angular deviations. Adjusted regression analyses retained TPD and distal EA in the mesial ΔMBL model and VAD in the mean ΔMBL model. Chairside, FG flapless implant placement improved positional accuracy and was associated with modest unadjusted differences in short-term marginal bone level changes after crestal sinus augmentation. However, the between-group differences in ΔMBL were not statistically significant after adjustment for multiple comparisons. Clinical Research Information Service of the National Research Institute of Health, South Korea (KCT0005465), Registered October 12, 2020. https://cris.nih.go.kr/cris/search/detailSearch.do?seq=26961&search_page=L.

PMID 42929132
阅读全文 →
PubMedDiseases (Basel, Switzerland)2026-10-26

Role of Interleukin 17 in Severe Acute Pancreatitis: Human Retrospective Pilot Study.

Iosif Diana D, Gherghina Viorel V, Suceveanu Andra Iulia AI, Orasanu Cristian Ionut CI et al.

Background/Objectives: Severe acute pancreatitis accounts for 20% of acute pancreatitis episodes and carries a substantial mortality risk. The systematic severity of the disease is driven by a massive cytokine release, with Interleukin-17 (IL-17) acting as a crucial modulator of the pro-inflammatory cascade. This study aimed to evaluate the prognostic value of serum IL-17 at admission and correlate it with multi-organ dysfunctions and clinical-biological outcomes in patients with severe acute pancreatitis. Methods: A retrospective analysis was conducted on a cohort of 35 patients with severe acute pancreatitis. Demographic, etiological, and clinical-biological baseline characteristics were extracted. Serum IL-17 levels were determined at admission using the ELISA method, and data were statistically analyzed. Results: Significantly higher levels of IL-17 were observed in patients who developed multi-organ failure. Prognostic thresholds were identified via ROC analysis to predict organ dysfunctions: ≥19.77 pg/mL for neurological dysfunction (AUC = 0.814, p = 0.003) and acute respiratory distress syndrome (AUC = 0.756, p = 0.024); ≥18.45 pg/mL for respiratory (p = 0.004) and cardiovascular dysfunctions (AUC = 0.820, p = 0.002); and ≥19.81 pg/mL for renal dysfunction (AUC = 0.735, p = 0.020). Furthermore, univariate binary logistic regression identified elevated serum IL-17 as a significant prognostic factor for mortality among patients admitted to the intensive care unit (OR = 1.062, p = 0.048). Conclusions: Serum IL-17 at admission functions as a significant prognostic biomarker that reflects the severe systemic pro-inflammatory status in severe acute pancreatitis and mirrors the risk of subsequent organ dysfunctions and mortality. Incorporating IL-17 into initial risk stratification protocols may assist clinicians in timely therapeutic escalation.

PMID 42929978
阅读全文 →
PubMedBiosensors2026-10-26

Physics-Guided Neural Phase Demodulation for Non-Contact Laser-Ultrasound Sensing of Corneal Phantom Deformation.

Awais Muhammad M, Kim Younggue Y, Lee Byeong Ha BH

Non-contact detection of weak, transient acoustic signals is essential for photoacoustic and laser-ultrasound (LUS) bioimaging, including the assessment of corneal deformation and thickness variation. Passive 3 × 3 fiber-coupler interferometers provide phase-diverse sensing without external modulation; however, conventional ellipse-based calibration becomes unreliable when the measured phase excursion covers only a small fraction of the characteristic ellipse, as in nanometer-scale corneal responses. This study presents a physics-guided temporal convolutional network (PG-TCN) that directly maps two nonideal interferometric outputs to a continuous dynamic phase signal without ellipse fitting or separate phase unwrapping during inference. The model combines dilated one-dimensional convolutions with interferometric-consistency and temporal-regularization losses. Tests using PZT-modulated calibration signals acquired under several static chamber pressures of 10, 15, 20, and 25 kPa showed lower mean absolute error, higher normalized cross-correlation, and lower displacement RMSE than a CNN-LSTM baseline. In corneal-phantom LUS measurements, the first detected echo shifted from 4.632 to 4.488 µs between 10 and 20 kPa, corresponding to a relative thickness reduction of approximately 7.8 µm/kPa. The PG-TCN required 210 ± 18 µs per sequence while using approximately half the trainable parameters of the CNN-LSTM baseline. These results demonstrate a fast physics-guided optical detection framework for non-contact sensing of weak acoustic responses, supporting the use of 3 × 3 optical interferometry as a biosensing approach for LUS and photoacoustic applications.

PMID 42930124
阅读全文 →
PubMedBiomimetics (Basel, Switzerland)2026-10-26

Chameleon Swarm Algorithm Applied to Extract the Parameters of Photovoltaic Cells and Panels.

Madhiarasan Manoharan M, Cotfas Petru A PA, Cotfas Daniel T DT

Forecasting the energy output of photovoltaic modules is an important consideration for prosumers and investors. The forecast accuracy depends on the precise determination of key external and internal parameters. This study proposes applying the metaheuristic Chameleon Swarm Algorithm (CSA) to extract the parameters for two photovoltaic cells, RTC France and aSi:H amorphous silicon, and one photovoltaic module, PWP 201. The CSA is applied to the most widely used models, which derive from the equivalent circuits for the photovoltaic cells and modules, namely with one, two, and three diodes. Six statistical metrics are used to verify and validate the performance of the CSA. The study also reports the following metrics: mean, standard deviation, minimum, maximum and interquartile range to evaluate the reliability and robustness of the algorithm. It is compared with several algorithms from 2023 to 2025 and some very good algorithms from outside of this interval. Computing time is also analyzed depending on the photovoltaic cells and module, the three models, and the number of iterations. The results for the main statistical metrics, root mean square error (RMSE), and computing time prove that the CSA is one of the most effective and reliable. The obtained RMSE is the best in some cases or equal, and the computing time is very low, thus certifying that the CSA is competitive against, and in several cases improves upon, previously reported best-known algorithms' results.

PMID 42930258
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多PG-201